Table 1:
Characteristics of participants in primary analyses
| Number of cohorts | BCG-vaccinated participants | Non-BCG-vaccinated participants | All participants | |
|---|---|---|---|---|
|
| ||||
| Outcomes analysed | ||||
| All tuberculosis | 26 | 49686 | 18866 | 68552 |
| Pulmonary tuberculosis | 14 | 41118 | 16161 | 57279 |
| Extrapulmonary tuberculosis | 14 | 40315 | 15868 | 56183 |
| Mortality | 4 | 16780 | 1395 | 18175 |
| Contact characteristics | ||||
| Age group | ||||
| <5 years | 23 | 9225/49686 (18·6%) | 1312/18866 (7·0%) | 10537/68552 (15·4%) |
| 5–9 years | 21 | 9936/49686 (20·0%) | 1289/18866 (6·8%) | 11225/68552 (16·4%) |
| 10–14 years | 19 | 7847/49686 (15·8%) | 1190/18866 (6·3%) | 9037/68552 (13·2%) |
| 15–24 years | 11 | 7984/49686 (16·1%) | 2628/18866 (13·9%) | 10612/68552 (15·5%) |
| 25–34 years | 11 | 5159/49686 (10·4%) | 3006/18866 (15·9%) | 8165/68552 (11·9%) |
| ≥35 years | 11 | 9535/49686 (19·2%) | 9441/18866 (50·0%) | 18976/68552 (27·7%) |
| Sex | ||||
| Female | 26 | 26421/49600 (53·3%) | 11208/18752 (59·8%) | 37629/68352 (55·1%) |
| Male | 26 | 23179/49600 (46·7%) | 7544/18752 (40·2%) | 30723/68352 (44·9%) |
| TST or IGRA positive | 25 | 13543/33474 (40·5%) | 3121/7068 (44·2%) | 16664/40543 (41·1%) |
| Living with HIV | 15 | 233/15119 (1·5%) | 87/3693 (2·4%) | 320/18812 (1·7%) |
| Previous tuberculosis | 17 | 1274/33812 (3·8%) | 542/17746 (3·1%) | 1816/51288 (3·5%) |
| Median follow-up, years | 26 | 2·0 (1·0–2·3) | 2·0 (1·9–2·1) | 2·0 (1·2–2·1) |
| Study characteristics | ||||
| Prospective study design | 20 | 38020/49686 (76·5%) | 17658/18866 (93·6%) | 55678/68552 (81·2%) |
| Latitude | ||||
| 0° to <10° | 5 | 3470/49686 (7·0%) | 846/18866 (4·5%) | 4316/68552 (6·3%) |
| 10° to <20° | 9 | 31680/49686 (63·8%) | 16154/18866 (85·6%) | 47834/68552 (69·8%) |
| 20° to <30° | 8 | 13024/49686 (26·2%) | 935/18866 (5·0%) | 13959/68552 (20·4%) |
| 30° to <40° | 4 | 1363/49686 (2·7%) | 930/18866 (4·9%) | 2293/68552 (3·3%) |
| ≥40° | 1 | 149/49686 (0·3%) | 1/18866 (<0·1%) | 150/68552 (0·2%) |
| Country income status* | ||||
| High | 1 | 9241/49686 (18·6%) | 170/18866 (0·9%) | 9411/68552 (13·7%) |
| Upper-middle | 13 | 16 075/49686 (32·4%) | 3573/18866 (18·9%) | 19 648/68552 (28·7%) |
| Lower-middle | 4 | 16253/49686 (32·7%) | 11670/18866 (61·9%) | 27923/68552 (40·7%) |
| Low | 6 | 8117/49686 (16·3%) | 3453/18866 (18·3%) | 11570/68552 (16·9%) |
| High WHO tuberculosis burden† | 14 | 21966/49686 (44·2%) | 13662/18866 (72·4%) | 35628/68552 (52·0%) |
| WHO region* | ||||
| African region | 10 | 9144/49686 (18·4%) | 3656/18866 (19·4%) | 12800/68552 (18·7%) |
| Region of the Americas | 9 | 14563/49686 (29·3%) | 2642/18866 (14·0%) | 17205/68552 (25·1%) |
| Eastern Mediterranean region | 0 | ·· | ·· | ·· |
| South-East Asia region | 4 | 1989/49686 (4·0%) | 461/18866 (2·4%) | 2450/68552 (3·6%) |
| Western Pacific region | 3 | 23841/49686 (48·0%) | 12106/18866 (64·2%) | 35947/68552 (52·4%) |
| European region | 1 | 149/49686 (0·3%) | 1/18866 (<0·1%) | 150/68552 (0·2%) |
Data are n or n (%) or median (IQR) unless otherwise specified. Denominators vary due to missing data. IGRA=IFNγ release assay. TST=tuberculin skin test.
*
Studies were grouped into WHO global regions and World Bank country-level economies as of October, 2018.
†
Studies were designated as being located in a country with a high burden of tuberculosis, as classified by WHO.